Page last updated: 2024-08-24

plerixafor and Lymphoma

plerixafor has been researched along with Lymphoma in 55 studies

Research

Studies (55)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (1.82)29.6817
2010's48 (87.27)24.3611
2020's6 (10.91)2.80

Authors

AuthorsStudies
Brunn, A; Deckert, M; Montesinos-Rongen, M; Sanchez-Ruiz, M; Siebert, R; Siebert, S; Winter, C1
Bosman, P; Boumendil, A; Celanovic, M; Chabannon, C; Dabrowska-Iwanicka, A; Dreger, P; Esquirol, A; Janikova, A; Jantunen, E; Liu, Q; Masszi, T; Montoto, S; Pohlreich, D; Russell, N; Sakellari, I; Scheid, C; Sureda, A; Thieblemont, C; Touzeau, C; van der Werf, S; Wahlin, BE1
Alvarado-Navarro, DM; Cantú-Rodríguez, OG; Colunga-Pedraza, PR; Del Carmen Tarín-Arzaga, L; Flores-Jiménez, JA; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; León, AG; Mejía-Jaramillo, G; Palomares-Leal, A; Salazar-Riojas, R; Sotomayor-Duque, G1
Ali, S; Babae, N; Glerum, PJ; Herberts, C; Herold, R; Josephson, F; Karres, D; Papadouli, I; Pignatti, F; Straus, S; Thole, G; van Hennik, PB1
Avalon, M; Bijou, F; Brunet de la Grange, P; Cabantous, T; Debeissat, C; Duchez, P; Ivanovic, Z; Mombled, M; Pasquet, JM; Pérard, B; Rodriguez, L; Sawai, KM; Thévenot, F; Vlaski-Lafarge, M1
Araki, Y; Furuta, Y; Komatsu, N; Miyake, K; Nakamura, Y; Noguchi, M; Ohsaka, A; Okubo, M; Osawa, T; Sawada, T; Sekiguchi, Y; Tada, N; Yamatoya, K1
Abu-Arja, R; Bhunia, N; Dalal, JD; Goyal, RK; Kang, HJ; Lee, AC; Loeb, DM; Mehyar, LS; O'Brien, TA; Ozkaynak, MF; Rangarajan, HG; Roberts, CH; Shaw, PJ; Shenoy, SS; Stanek, JR; Stein, J; Strahlendorf, C1
Gawroński, K; Rzepecki, P; Sawicki, W; Wajs, J1
Bosse, R; Duyster, J; Engelhardt, M; Greil, C; Hildenbeutel, S; Ihorst, G; Kiote-Schmidt, C; Kühbach, K; Wäsch, R1
Culligan, DJ; Dong, B; Hay, AE; Lawrie, A; Robinson, N1
Kogut, N; Krishnan, A; Nademanee, A; Shayani, S; Wang, S; Yuan, S1
Abdel-Rahman, F; Al Rawi, O; Hussein, A; Hussein, N; Jazar, HA; Saad, A; Sharma, S; Tuffaha, HW1
Bosi, A; Cascavilla, N; Guggiari, E; Imola, M; Lanza, F; Laszlo, D; Lemoli, RM; Martinelli, G; Martino, M; Milone, G; Olivieri, A; Pasini, A; Pavone, V; Rambaldi, A; Scortechini, I; Specchia, G; Todisco, E1
Kořístek, Z; Lysák, D; Tichopád, A; Vítová, V1
Nademanee, A; Salhotra, A; Wang, S; Yuan, S1
Cupri, A; Di Marco, A; Di Martina, V; Leotta, S; Martino, M; Milone, G; Scalzulli, P; Schinocca, E; Spadaro, A; Spina, E; Tripepi, G1
Carlo-Stella, C; Corradini, P; Farina, L; Guidetti, A; Longoni, P; Ravagnani, F; Roncari, L; Spina, F1
Andritsos, LA; Devine, SM; Haverkos, BM; Jaglowski, SM; McBride, A; O'Donnell, L; Penza, S; Scholl, D; Vasu, S; Whittaker, B1
Came, N; Demosthenous, L; Harrison, S; Herbert, KE; Link, E; Prince, HM; Ritchie, DS; Seymour, JF; Westerman, DA; Wiesner, G1
Budisavljevic, MN; Butcher, C; Chhabra, S; Costa, LJ; Edwards, KH; Kang, Y; Kramer, C; Littleton, A; Schade, H; Schneider, M; Stuart, RK1
Jang, JH; Jung, CW; Jung, SK; Kang, ES; Kim, DW; Kim, K; Kim, SJ; Kim, WS; Lee, KH1
Barba, P; Duarte, RF; Encuentra, M; Esquirol, A; Garcia-Cerecedo, T; Grifols, JR; Martí, JM; Ortega, S; Pujol-Balaguer, MM; Pujol-Bosch, M; Querol, S; Sánchez-Ortega, I; Sanchez-Villegas, JM; Sancho, JM; Serra, A; Sierra, J1
André, M; Baily, L; Dierickx, D; Huyngh, P; Lambert, C; Noens, L; Selleslag, D; Van de Velde, A; Willems, E; Zachee, P1
Bell, J; Braithwaite, B; Callaghan, T; Clark, JO; Clark, RE; Francis, S; McGinnity, N; Salim, R; Vithanarachchi, U1
Flowers, C; Gaylor, C; Harvey, RD; Jagirdar, N; Kaufman, J; Langston, A; Lechowicz, MJ; Lipscomb, C; Lonial, S; Nooka, A; Waller, EK1
Bell, J; Braithwaite, B; Clark, JO; Clark, RE; Haycox, A; Houten, R; Martin, AP; McLeod, C; Richards, S1
Craig, M; Cumpston, A; Hamadani, M; Kanate, AS; Leadmon, S; Luo, J; Shillingburg, A; Veltri, L; Watkins, K; Wen, S1
Engert, A; Hartmann, T; Hübel, K; Monsef, I; Skoetz, N1
Cho, SG; Do, YR; Eom, HS; Kim, H; Kim, JS; Kim, WS; Kwak, JY; Lee, J; Lee, JJ; Min, CK; Moon, JH; Park, S; Suh, C; Yang, DH; Yoon, DH; Yoon, SS1
Baker, J; Cooper, DL; Foss, F; Medoff, E; Patel, N; Perreault, S; Pratt, K; Seropian, SE; Wu, Y1
Duarte, R; Marín, P; Medina, L; Querol, S; Sancho, JM; Sureda, A1
Jantunen, E; Mäntymaa, P; Nousiainen, T; Partanen, A; Pyörälä, M; Valtola, J; Varmavuo, V1
Achtereekte, H; de la Rubia, J; Delgado, J; Douglas, KW; Duarte, RF; Gandhi, PJ; Gayoso, J; Goterriz, R; Kottaridis, P; Marín, P; Martínez-Chamorro, C; Mateos-Mazón, JJ; Morante, C; Ortiz, M; Ramírez, C; Russell, NH; Shaw, BE1
Alexander, ET; Costa, LJ; Fouts, TV; Hogan, KR; Schaub, C; Stuart, RK1
Agis, H; Baccarani, M; Casadei, B; Curti, A; D'Addio, A; Dan, E; Douglas, K; Giudice, V; Kopetzky, G; Lemoli, RM; Motta, MR; Rizzi, S; Soutar, R; Taioli, S; Worel, N1
Greinix, HT; Kalhs, P; Kasparu, H; Linkesch, W; Nachbaur, D; Namberger, K; Neumeister, P; Rosskopf, K; Russ, G; Schloegl, E; Witt, V; Worel, N; Zojer, N1
Jantunen, E; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Pyörälä, M1
Arakawa, F; Ohshima, K; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M1
Alamos, SM; Antoniazzi, F; Arcaini, L; Balzarotti, M; Bonfichi, M; Farina, L; Guggiari, E; Laszlo, D; Martinelli, G; Morra, E; Rizzi, S; Rossi, G; Todisco, E; Zilioli, VR1
Worel, N1
Anderson, D; Flowers, CR; Gleason, C; Graiser, M; Hamilton, E; Kaufman, JL; Langston, A; Lechowicz, MJ; Li, J; Lonial, S; Prichard, JM; Renfroe, H; Vaughn, L; Waller, EK1
Baker, J; Conkling-Walsh, A; Cooper, DL; Foss, F; Medoff, E; Pratt, K; Seropian, SE; Snyder, E; Yen, W1
Fogle, R; Gale, M; Garron, C; Hu, Y; Jacques, G; Kaplan, J; Nguyen, TH; Shields, J; Siders, W; Swistak, M1
Attolico, I; Coluzzi, S; Crescimanno, A; Di Nardo, E; Iacopino, P; Martino, M; Milone, G; Musso, M; Nuccorini, R; Olivieri, A; Ostuni, A; Pascale, S; Pavone, V; Rossini, B; Tedeschi, P1
Jantunen, E1
Keating, GM1
Andreola, G; Babic, A; Laszlo, D; Martinelli, G; Negri, M; Rabascio, C1
DiPersio, JF1
Bensinger, WI; Gopal, AK; Holmberg, L; Karami, M; Linenberger, M; Macebeo, M; Mayor, J1
Butcher, CD; Costa, LJ; Hogan, KR; Kang, Y; Kramer, C; Littleton, AL; Shoptaw, KB; Stuart, RK1
Bains, T; Bubalo, J; Chen, AI; Fowler, C; Knight, R; Maziarz, RT; Murray, S; Shoop, K; Slater, S1
Akı, SZ; Altuntaş, F; Ayyıldız, E; Baysal, NA; Dönmez, A; Ilhan, O; Sarı, I; Sıvgın, S; Tekgündüz, E; Tombuloğlu, M; Topçuoğlu, P; Unal, A; Yıldırım, R; Yüksel, MK1
Calandra, GB; Flowers, CR; Hewes, LB; Kaufman, JL; Khoury, HJ; Langston, AA; Lechowicz, MJ; Lonial, S; Rados, KD; Vose, JM; Waller, EK1
Calandra, G; DiPersio, J; Flomenberg, N1

Reviews

6 review(s) available for plerixafor and Lymphoma

ArticleYear
EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
    The oncologist, 2020, Volume: 25, Issue:6

    Topics: Adult; Benzylamines; Child; Cyclams; Europe; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Transplantation, Autologous

2020
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    The Cochrane database of systematic reviews, 2015, Oct-20, Issue:10

    Topics: Benzylamines; Cyclams; Early Termination of Clinical Trials; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Time Factors; Transplantation, Autologous

2015
CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target.
    Brain tumor pathology, 2011, Volume: 28, Issue:2

    Topics: Benzylamines; Brain Neoplasms; Cell Movement; Chemokine CXCL12; Cyclams; Glioblastoma; Heterocyclic Compounds; Humans; Lymphoma; Neoplasm Metastasis; Protein Binding; Receptors, CXCR4; Signal Transduction; Stem Cells

2011
Novel strategies for blood stem cell mobilization: special focus on plerixafor.
    Expert opinion on biological therapy, 2011, Volume: 11, Issue:9

    Topics: Animals; Anti-HIV Agents; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia; Lymphoma; Multiple Myeloma; Stem Cell Transplantation

2011
Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
    Drugs, 2011, Aug-20, Volume: 71, Issue:12

    Topics: Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma

2011
Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.
    Acta haematologica, 2005, Volume: 114, Issue:4

    Topics: Anti-HIV Agents; Benzylamines; Bone Marrow; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Clinical Trials as Topic; Cyclams; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Protein Binding; Receptors, CXCR4; Recombinant Proteins; Transplantation, Autologous

2005

Trials

11 trial(s) available for plerixafor and Lymphoma

ArticleYear
Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
    Transfusion, 2019, Volume: 59, Issue:12

    Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Proof of Concept Study; Transplantation, Autologous

2019
An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.
    Bone marrow transplantation, 2014, Volume: 49, Issue:8

    Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation

2014
Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Bone marrow transplantation, 2014, Volume: 49, Issue:8

    Topics: Adult; Anti-HIV Agents; Autografts; Benzylamines; Blood Component Removal; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins

2014
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.
    Transfusion, 2014, Volume: 54, Issue:12

    Topics: Aged; Anti-HIV Agents; Antigens, CD34; Autografts; Benzylamines; Blood Component Removal; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies

2014
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
    Bone marrow transplantation, 2015, Volume: 50, Issue:1

    Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Autografts; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Risk Factors

2015
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.
    Blood cancer journal, 2014, Oct-31, Volume: 4

    Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukapheresis; Lymphoma; Male; Middle Aged; Multiple Myeloma

2014
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Transfusion, 2015, Volume: 55, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cyclophosphamide; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Vincristine

2015
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experienc
    Transfusion, 2011, Volume: 51, Issue:5

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Austria; Benzylamines; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunoglobulin G; Leukapheresis; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Transplantation, Autologous; Young Adult

2011
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
    Leukemia research, 2011, Volume: 35, Issue:6

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Combined Modality Therapy; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Treatment Outcome; Young Adult

2011
Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recovery of Function; Transplantation, Autologous

2012
Plerixafor use in patients with previous mobilization failure: A multicenter experience.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2012, Volume: 47, Issue:1

    Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous

2012

Other Studies

38 other study(ies) available for plerixafor and Lymphoma

ArticleYear
AMD3100-Mediated CXCR4 Inhibition Impairs Development of Primary Lymphoma of the Central Nervous System.
    The American journal of pathology, 2023, Volume: 193, Issue:8

    Topics: Animals; Benzylamines; Brain; Chemokine CXCL12; Lymphoma; Mice; Receptors, CXCR4; Signal Transduction

2023
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.
    Bone marrow transplantation, 2020, Volume: 55, Issue:3

    Topics: Benzylamines; Bone Marrow; Cyclams; Europe; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Neoplasm Recurrence, Local; Registries

2020
Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization.
    Leukemia, 2020, Volume: 34, Issue:12

    Topics: Animals; Antigens, CD34; Benzylamines; Child; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Mice; Middle Aged; Multiple Myeloma; Stem Cells

2020
Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2021, Volume: 25, Issue:5

    Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hospitals, University; Humans; Japan; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cells; Transplantation, Autologous

2021
A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.
    Transfusion, 2021, Volume: 61, Issue:3

    Topics: Adolescent; Antigens, CD34; Benzylamines; Blood Component Removal; Child; Child, Preschool; Cohort Studies; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Humans; Infant; Lymphoma; Male; Medulloblastoma; Neoplasms; Neuroblastoma; Peripheral Blood Stem Cells; Retrospective Studies; Sarcoma; Young Adult

2021
Mobilization of Hematopoietic Stem Cells for Hematopoietic Cells Autologous Transplantation with Use of Plerixafor.
    Annals of transplantation, 2017, May-12, Volume: 22

    Topics: Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome

2017
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:7

    Topics: Benzylamines; Cell Count; Cost-Benefit Analysis; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome

2018
A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
    Journal of clinical apheresis, 2013, Volume: 28, Issue:5

    Topics: Antigens, CD34; Benzylamines; Blood Component Removal; Body Weight; Cost-Benefit Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2013
Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.
    Transfusion, 2013, Volume: 53, Issue:12

    Topics: Adult; Aged; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy

2013
GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: collection effectiveness and cost effectiveness analysis.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:2

    Topics: Adult; Benzylamines; Cost-Benefit Analysis; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Retrospective Studies; Young Adult

2014
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.
    Transfusion, 2014, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Aged; Benzylamines; Blood Component Removal; Chemoradiotherapy; Cyclams; Data Collection; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Italy; Leukapheresis; Lymphoma; Male; Middle Aged; Multiple Myeloma; Platelet Count; Predictive Value of Tests; Prospective Studies; Receptors, CXCR4; Young Adult

2014
Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
    Journal of clinical apheresis, 2013, Volume: 28, Issue:6

    Topics: Adolescent; Adult; Aged; Benzylamines; Child; Child, Preschool; Cost-Benefit Analysis; Cyclams; Cytapheresis; Czechoslovakia; Decision Trees; Female; Granulocyte Colony-Stimulating Factor; Health Expenditures; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Infant; Length of Stay; Lymphoma; Male; Middle Aged; Models, Economic; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome; Young Adult

2013
Plerixafor to the rescue: boosting peripheral blood stem cell mobilization in patients previously treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine (Hyper-CVAD) chemotherapy.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Treatment Outcome; Vincristine

2014
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
    British journal of haematology, 2014, Volume: 164, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Retrospective Studies; Young Adult

2014
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.
    Bone marrow transplantation, 2014, Volume: 49, Issue:3

    Topics: Adult; Aged; Algorithms; Antigens, CD34; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged

2014
Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Vox sanguinis, 2014, Volume: 107, Issue:4

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Incidence; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Transplantation, Autologous

2014
Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.
    Acta clinica Belgica, 2015, Volume: 70, Issue:1

    Topics: Adult; Aged; Belgium; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prospective Studies; Transplantation, Autologous

2015
Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.
    Journal of clinical apheresis, 2016, Volume: 31, Issue:5

    Topics: Benzylamines; Cost-Benefit Analysis; Costs and Cost Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Historically Controlled Study; Humans; Lymphoma; Multiple Myeloma

2016
Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
    Cytotherapy, 2015, Volume: 17, Issue:12

    Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cost-Benefit Analysis; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Young Adult

2015
Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicent
    Annals of hematology, 2016, Volume: 95, Issue:4

    Topics: Adult; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Prognosis; Republic of Korea; Retrospective Studies; Treatment Failure; Young Adult

2016
Autologous Stem Cell Mobilization in the Age of Plerixafor.
    Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:7

    Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Workflow

2016
[Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Medicina clinica, 2016, Sep-02, Volume: 147, Issue:5

    Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Transplantation, Autologous

2016
Pre-emptive plerixafor injection in lymphoma patients mobilized with chemotherapy plus pegfilgrastim followed by apheresis on the same day.
    Journal of clinical apheresis, 2017, Volume: 32, Issue:6

    Topics: Adult; Aged; Benzylamines; Blood Component Removal; Cyclams; Female; Filgrastim; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Polyethylene Glycols; Premedication; Time Factors

2017
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Bone marrow transplantation, 2011, Volume: 46, Issue:1

    Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cohort Studies; Compassionate Use Trials; Cyclams; Drug Therapy, Combination; European Union; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2011
Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
    Bone marrow transplantation, 2011, Volume: 46, Issue:1

    Topics: Algorithms; Antigens, CD34; Benzylamines; Blood Cell Count; Blood Component Removal; Cohort Studies; Cost Savings; Cyclams; Decision Support Techniques; Drug Therapy, Combination; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous

2011
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
    Bone marrow transplantation, 2011, Volume: 46, Issue:3

    Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous

2011
Plerixafor. Only for certain patients when G-CSF stem cell mobilisation fails.
    Prescrire international, 2010, Volume: 19, Issue:108

    Topics: Benzylamines; Clinical Trials as Topic; Cyclams; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Receptors, CXCR4

2010
Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
    European journal of haematology, 2011, Volume: 86, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Receptors, CXCR4; Recombinant Proteins; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2011
Plerixafor--the magic bullet in stem cell mobilization failure?
    Leukemia research, 2011, Volume: 35, Issue:6

    Topics: Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Peripheral Blood Stem Cell Transplantation

2011
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Transfusion, 2011, Volume: 51, Issue:10

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cohort Studies; Cost-Benefit Analysis; Cyclams; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation, Autologous; Young Adult

2011
Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:3

    Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cell Count; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult

2011
Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:1

    Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Chemotaxis; Cyclams; Drug Synergism; Flow Cytometry; Heterocyclic Compounds; Humans; Lymphoma; Mice; Mice, SCID; Phosphorylation; Pyridines; Receptors, CXCR4; Rituximab; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays

2012
Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
    European journal of haematology, 2012, Volume: 88, Issue:2

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow Transplantation; Combined Modality Therapy; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Transplantation, Autologous; Treatment Outcome; Young Adult

2012
New hope for mobilization failures . . . again.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2

    Topics: Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation

2012
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.
    Journal of clinical apheresis, 2012, Volume: 27, Issue:2

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Dexamethasone; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kinetics; Lymphoma; Middle Aged; Multiple Myeloma

2012
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Transfusion, 2012, Volume: 52, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Cost-Benefit Analysis; Cyclams; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome

2012
Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization.
    Bone marrow transplantation, 2012, Volume: 47, Issue:12

    Topics: Adult; Aged; Algorithms; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Paraproteinemias; Transplantation, Autologous; Treatment Outcome

2012
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
    Transfusion, 2013, Volume: 53, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Lymphoma; Rituximab; Stem Cell Transplantation

2013